Aldesleukin (Recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma (vol 7, pg 285, 1997)

被引：0
|
作者：
Jeal, W
Goa, KL
机构：
来源：
BIODRUGS | 1997年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [21] SUBCUTANEOUS LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA (VOL 69, PG 1111, 1994)
    RAVAUD
    BRITISH JOURNAL OF CANCER, 1994, 70 (06) : 1284 - 1284
  • [22] Formoterol: a review of its pharmacological properties and therapeutic efficacy in the management of asthma. (vol 55, pg 303, 1997)
    Bartow, RA
    Brogden, RN
    DRUGS, 1998, 55 (04) : 517 - 517
  • [23] Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma (vol 23, pg 133, 2005)
    McDermott
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2877 - 2877
  • [24] Observational study in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 (rIL-2).
    García, A. G., Sr.
    Esteban, E.
    Giron, C. G.
    Maroto, P.
    Andres, R.
    Canelas, A.
    Caballido, J.
    Carles, J.
    Espinosa, E.
    Lacave, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [25] A PROGRESS REPORT ON THE OUTPATIENT TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA USING SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2
    BUTER, J
    SLEIJFER, DT
    VANDERGRAAF, WTA
    DEVRIES, EGE
    WILLEMSE, PHB
    MULDER, NH
    SEMINARS IN ONCOLOGY, 1993, 20 (06) : 16 - 21
  • [26] Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma - A phase II study
    Creagan, ET
    Hestorrf, RD
    Suman, VJ
    Mailliard, JA
    Nair, S
    Krook, JE
    Kugler, JW
    Marschke, RF
    Michalak, JC
    Tschetter, LK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (02): : 139 - 141
  • [27] IMMUNOLOGICAL STUDY OF HUMAN RECOMBINANT INTERLEUKIN-2 (LOW-DOSE) IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    MARUMO, K
    MURAKI, J
    UENO, M
    TACHIBANA, M
    DEGUCHI, N
    BABA, S
    JITSUKAWA, S
    HATA, M
    TAZAKI, H
    UROLOGY, 1989, 33 (03) : 219 - 225
  • [28] Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    Fisher, RI
    Rosenberg, SA
    Fyfe, G
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 2000, 6 : S55 - S57
  • [29] Adapalene: A review of its pharmacological properties and clinical potential in the management of mild to moderate acne (vol 53, pg 511, 1997)
    Brogden, RN
    Goa, KL
    DRUGS, 1997, 53 (05) : 827 - 827
  • [30] CLINICAL AND BIOLOGICAL RESPONSES FOLLOWING INTERLEUKIN-2 THERAPY IN PATIENTS WITH METASTATIC MELANOMA AND RENAL-CELL CARCINOMA
    DORREEN, MS
    SHERIDAN, E
    SREENIVASAN, T
    HAYAT, K
    ROGERS, S
    BRUCE, L
    HANCOCK, BW
    CHAPMAN, K
    REES, RC
    BRITISH JOURNAL OF CANCER, 1991, 63 (05) : 833 - 834
12345